REGN — Regeneron Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $81.99bn
- $76.70bn
- $14.34bn
Merck's cholesterol pill gets US FDA approval
U.S. RESEARCH ROUNDUP-East West Bancorp, First Citizens Bancshares, UMB Financial
Lilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)
AbbVie strikes $10.9 billion deal for Apogee Therapeutics
Drug developer Parabilis Medicines surges in Nasdaq debut
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Parabilis Medicines targets $2.3 billion valuation in upsized US IPO (updated)
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Brief: Parabilis Medicines - Estimated IPO Price Per Share Between $17 And $19 - SEC Filing
CytomX rises on expanded Regeneron deal worth up to $4 billion
CytomX rises on expanded Regeneron deal with up to $4 billion in milestones
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Brief: Regeneron’S Ebola Antibody Recommended By World Health Organization For Investigational Use In Response To Current Bundibugyo Ebolavirus Outbreak